Iovance Biotherapeutics
IOVA
77 hedge funds and large institutions have $183M invested in Iovance Biotherapeutics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 17 reducing their positions, and 16 closing their positions.
599% more call options, than puts
Call options by funds: $2.95M | Put options by funds: $422K
71% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 82 → 77 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
33% less capital invested
Capital invested by funds: $271M → $183M (-$88.7M)
Top Buyers
| 1 |
Axa
Paris,
France
|
+$4.35M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.2M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.79M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$1.37M |
| 5 |
QF
QVT Financial
New York
|
+$901K |
Top Sellers
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$4.11M |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$1.54M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.17M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$950K |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$342K |
IOVA Hedge Fund Activity: Q1 2016 in Review
77 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2016, worth a combined $183M — down 33% from $271M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IOVA and 11 opened new positions — a net loss of 5 holders — while 17 trimmed existing stakes and 29 added.
The largest buyer was Axa, opening a new position worth an estimated $4.35M. The largest seller was Baker Bros. Advisors, cutting an estimated $4.11M.
- 77 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2016, down from 82 in Q4 2015.
- Funds reported $183M of Iovance Biotherapeutics stock for Q1 2016, down 33% quarter-over-quarter.
- 11 funds opened new Iovance Biotherapeutics positions in Q1 2016 and 16 closed out, a net change of -5 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2016 was Axa, an estimated $4.35M added.
- The largest Iovance Biotherapeutics seller in Q1 2016 was Baker Bros. Advisors, an estimated $4.11M sold.
Based on aggregated 13F filings for Q1 2016.